|
|
Article: NeoPharm Investigators Present Preliminary Phase I Data of Cintredekin Besudotox in the Treatment of Malignant Glioma at Initial Diagnosis.
- Article from:
- Business Wire
- Article date:
- October 10, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LAKE FOREST, Ill. -- NeoPharm, Inc. (Nasdaq:NEOL):
--Poster Presentation at the 55th Annual Meeting of the Congress of Neurological Surgeons
--No Unexpected Types of Adverse Events To Date in the Study
--Multimodality Treatment Regimen with Cintredekin Besudotox may be Feasible
NeoPharm, Inc. (Nasdaq:NEOL) today announced the presentation of initial safety data from a Phase I study of cintredekin besudotox in the treatment of newly diagnosed malignant glioma patients at the 55th Annual Meeting of the Congress of Neurological Surgeons (CNS) being held in Boston from October 8-13, 2005.
The main objective of this study is to ...